Application of pogonitone E in preparation of medicine for treating diabetic retinopathy

Abstract

The invention discloses an application of poticotinone E in preparation of a medicine for treating diabetic retinopathy, and belongs to the technical field of natural medicines. The invention relates to an application of pogonitone E in preparation of a medicine for treating diabetic retinopathy. The invention relates to an application of potigonone E or a pharmaceutically acceptable salt thereof in preparation of a medicament for treating diabetic retinopathy. The pharmaceutically acceptable salt is a salt formed by pomace E and an organic base or an inorganic base. The salt is sodium salt, potassium salt, calcium salt, ferric salt, magnesium salt, zinc salt, aluminum salt, barium salt or ammonium salt. The invention relates to a medicament for treating diabetic retinopathy, which is prepared into a pharmaceutically acceptable dosage form by taking pogonitone E as an active ingredient and also containing pharmaceutically acceptable auxiliary materials. Research finds that pogonitone E has a remarkable effect of treating diabetic retinopathy, a foundation is laid for development and utilization of pogonitone plants, and a foundation is laid for development and utilization of pogonitone E.

Description

Technical Field

[0001] The invention relates to application of tricholoma E in preparing a medicine for treating diabetic retinopathy, and belongs to the technical field of natural medicines. Background Art

[0002] The Chinese name of physostigmine E: 2-(4-(2,4-dimethoxybenzoyl)phenyl)-N-(2-methoxyphenyl)acetamide; English name: 2-(4-(2,4-dimethoxybenzoyl)phenyl)-N-(2-methoxyphenyl)acetamide. It is a benzophenone compound isolated from Taiwan physostigmine, which has good anti-colon cancer activity.

[0003] In order to develop and expand its medical use, the present invention is specially proposed. Summary of the invention

[0004] In view of the above problems, the purpose of the present invention is to provide a use of tricholoma E in the preparation of a drug for treating diabetic retinopathy.

[0005] In order to solve the above technical problems, the technical solution adopted by the present invention is:

[0006] Application of tricholoma E in the preparation of drugs for treating diabetic retinopathy.

[0007] The structural formula of goldenseal E is as follows:

[0008]

[0009] Application of tricholoma E or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating diabetic retinopathy.

[0010] The pharmaceutically acceptable salt is a salt formed by tricholon E and an organic base or an inorganic base.

[0011] The salt is a sodium salt, potassium salt, calcium salt, iron salt, magnesium salt, zinc salt, aluminum salt, barium salt or ammonium salt.

[0012] The drug uses tricholoma E as an active ingredient and also contains pharmaceutically acceptable excipients to be prepared into a pharmaceutically acceptable dosage form.

[0013] Excipients include any one or more of solvents, propellants, solubilizers, co-solvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids, and release retardants.

[0014] Dosage forms include tablets, capsules, injections and oral solutions.

[0015] A medicine for treating diabetic retinopathy is prepared from tricholoma E or a pharmaceutically acceptable salt thereof.

[0016] A drug for treating diabetic retinopathy, which uses tricholoma E as an active ingredient and also contains pharmaceutically acceptable excipients to be prepared into a pharmaceutically acceptable dosage form.

[0017] Application of tricholoma E or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating retinal diseases.

[0018] A medicine for treating retinal lesions is prepared from tricholoma E or a pharmaceutically acceptable salt thereof.

[0019] A drug for treating retinopathy, which takes tricholoma E as an active ingredient and also contains pharmaceutically acceptable excipients to be prepared into a pharmaceutically acceptable dosage form.

[0020] Application of tricholoma E or a pharmaceutically acceptable salt thereof in the preparation of a drug for promoting the proliferation of retinal pigment epithelial cells.

[0021] A drug for promoting retinal pigment epithelial cell proliferation is prepared from tricholoma E or a pharmaceutically acceptable salt thereof.

[0022] A drug for promoting retinal pigment epithelial cell proliferation uses tricholoma E as an active ingredient and also contains pharmaceutically acceptable excipients to prepare a pharmaceutically acceptable dosage form.

[0023] Compared with the prior art, the present invention has the following advantages:

[0024] Studies have found that goldenrod ketone E has a significant effect in treating diabetic retinopathy. The present invention lays a foundation for the development and utilization of goldenrod ketone plants and for the development and utilization of goldenrod ketone E. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1The figure shows the effect of different treatment groups on the proliferation activity of retinal pigment epithelial cells. Note: Compared with the Control group, ####P<0.0001; compared with the high glucose group, ****P<0.0001. DETAILED DESCRIPTION

[0026] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments. The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention.

[0027] Application of tricholoma E in the preparation of drugs for treating diabetic retinopathy.

[0028] Use of tricholoma E or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating diabetic retinopathy. The pharmaceutically acceptable salt is a salt formed by tricholoma E and an organic base or an inorganic base. The salt is a sodium salt, a potassium salt, a calcium salt, a ferric salt, a magnesium salt, a zinc salt, an aluminum salt, a barium salt or an ammonium salt.

[0029] A drug for treating diabetic retinopathy, which uses tricholoma E as an active ingredient and also contains pharmaceutically acceptable excipients to be prepared into a pharmaceutically acceptable dosage form.

[0030] Application of tricholoma E or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating retinal diseases.

[0031] A medicine for treating retinal lesions is prepared from tricholoma E or a pharmaceutically acceptable salt thereof.

[0032] A drug for treating retinopathy, which takes tricholoma E as an active ingredient and also contains pharmaceutically acceptable excipients to be prepared into a pharmaceutically acceptable dosage form.

[0033] Application of tricholoma E or a pharmaceutically acceptable salt thereof in the preparation of a drug for promoting the proliferation of retinal pigment epithelial cells.

[0034] A drug for promoting retinal pigment epithelial cell proliferation is prepared from tricholoma E or a pharmaceutically acceptable salt thereof.

[0035] A drug for promoting retinal pigment epithelial cell proliferation uses tricholoma E as an active ingredient and also contains pharmaceutically acceptable excipients to prepare a pharmaceutically acceptable dosage form.

[0036] Excipients include any one or more of solvents, propellants, solubilizers, co-solvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids, and release retardants.

[0037] Dosage forms include tablets, capsules, injections and oral solutions.

[0038] Pharmacological activity: pyruvate E has good activity in treating diabetic retinopathy.

[0039] Cell source: Retinal pigment epithelial cells ARPE-19 were purchased from the Cell Bank of the Chinese Academy of Sciences.

[0040] Cell culture and experimental grouping: The cells used were ARPE-19 cell line, cultured in DMEM / F-12 medium containing 10% fetal bovine serum and 1% penicillin / streptomycin at 37°C and 5% CO 2 The cells were cultured in a conventional incubator. When the cells grew to a density of about 85%, they were randomly divided into 6 groups, namely, the control group, the DMSO group, the high glucose group, the high glucose + 25 μmol / L tricholoma E group, the high glucose + 50 μmol / L tricholoma E group, and the high glucose + 100 μmol / L tricholoma E group. The compound tricholoma E was dissolved in 0.1% dimethyl sulfoxide (DMSO) to prepare a mother solution with a concentration of 10 mmol / L for later use.

[0041] Control group: cultured with 5mmol / L glucose for 24h;

[0042] DMSO group: cultured with 0.1% DMSO + 5mmol / L glucose for 24h;

[0043] High glucose group: cultured with 30mmol / L glucose for 24h;

[0044] The dosing group was divided into three dose groups:

[0045] They are: high glucose + 25 μmol / L tricholoma E group: cultured with 30 mmol / L glucose and 25 μmol / L tricholoma E for 24 h;

[0046] High glucose + 50 μmol / L tricholoma E group: cultured with 30 mmol / L glucose and 50 μmol / L tricholoma E for 24 h;

[0047] High glucose + 100 μmol / L tricholoma E group: cultured with 30 mmol / L glucose and 100 μmol / L tricholoma E for 24 h.

[0048] CCK-8 assay: Add 100 μL of cell suspension from each group to each well of a 96-well plate and place the plate in a 37°C, 5% CO 2 Pre-cultured in an incubator for 24 hours. Add 10 μL of CCK-8 solution to each well, culture in an incubator for 4 hours, and measure the absorbance at 450 nm with a microplate reader. The cell proliferation activity was obtained by calculating the ratio of the absorbance of the drug-added group to the absorbance of the control group. Compared with the Control group, the proliferation activity of retinal pigment epithelial cells in the high glucose group was significantly reduced (P < 0.0001); different doses of high glucose + tricholoma E groups could significantly improve and upregulate the proliferation activity of retinal pigment epithelial cells under high glucose conditions (P < 0.0001), and showed dose dependence, indicating that tricholoma E can promote the proliferation of retinal pigment epithelial cells. The results are shown in Table 1 and Figure 1 .

[0049] Table 1 Effects of different treatment groups on the proliferation activity of retinal pigment epithelial cells

[0050]

[0051]

[0052] It should be understood that in order to streamline the present disclosure and aid in understanding one or more of the various inventive aspects, in the above description of exemplary embodiments of the present invention, various features of the present invention are sometimes grouped together into a single embodiment, or description thereof. However, this disclosed method should not be interpreted as reflecting the intention that the claimed invention requires more features than those expressly recited in each claim. Rather, as reflected in the claims, inventive aspects lie in less than all of the features of the previously disclosed embodiments. Therefore, the claims that follow the detailed description are hereby expressly incorporated into the detailed description, with each claim itself serving as a separate embodiment of the present invention.

[0053] Although the present invention has been described according to a limited number of embodiments, it will be apparent to those skilled in the art, with the benefit of the above description, that other embodiments may be envisioned within the scope of the invention thus described. In addition, it should be noted that the language used in this specification is selected primarily for readability and teaching purposes, rather than for explaining or defining the subject matter of the present invention. Therefore, many modifications and variations will be apparent to those skilled in the art without departing from the scope and spirit of the appended claims. The disclosure of the present invention is illustrative, not restrictive, with respect to the scope of the present invention, which is defined by the appended claims.

[0054] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of tricholoma E in the preparation of drugs for the treatment of diabetic retinopathy.

2. The use according to claim 1, characterized in that: The structural formula of goldenseal E is as follows: 。 3. The use according to claim 1, characterized in that: Application of tricholoma E or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating diabetic retinopathy.

4. The use according to claim 3, characterized in that: The pharmaceutically acceptable salt is a salt formed by tricholon E and an organic base or an inorganic base.

5. The use according to claim 4, characterized in that: The salt is a sodium salt, potassium salt, calcium salt, iron salt, magnesium salt, zinc salt, aluminum salt, barium salt or ammonium salt.

6. The use according to claim 1, characterized in that: The drug uses tricholoma E as an active ingredient and also contains pharmaceutically acceptable excipients to be prepared into a pharmaceutically acceptable dosage form.

7. The use according to claim 6, characterized in that: Excipients include any one or more of solvents, propellants, solubilizers, co-solvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants, deflocculating agents, filter aids, and release retardants.

8. The use according to claim 6, characterized in that: Dosage forms include tablets, capsules, injections and oral solutions.

9. A drug for treating diabetic retinopathy, characterized in that: The invention is prepared from golden tricholon E or a pharmaceutically acceptable salt thereof.

10. The drug according to claim 9, characterized in that The drug uses tricholoma E as an active ingredient and also contains pharmaceutically acceptable excipients to be prepared into a pharmaceutically acceptable dosage form.

Images